FDA Approves New Oral PCSK9 Inhibitor to Drastically Reduce LDL Cholesterol

The U.S. Food and Drug Administration (FDA) has approved Enlicitide, the first oral PCSK9 inhibitor designed to lower LDL cholesterol. Developed by Merck, the medication can reduce low-density lipoprotein (LDL) levels by up to 60%, according to reporting from Yahoo Finanzas and CNN en Español.

This approval marks a shift in how clinicians can manage high cholesterol, moving a potent class of drugs from injectable forms to a daily pill. The medication targets the PCSK9 protein to help the liver clear more LDL cholesterol from the bloodstream, as noted by the Sociedad Chilena de Obesidad.

Enlicitide and the PCSK9 Inhibition Mechanism

Enlicitide functions as a PCSK9 inhibitor. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a protein that regulates the number of LDL receptors on the surface of liver cells. When PCSK9 is inhibited, more receptors remain available to capture and remove LDL cholesterol from the blood, according to the Sociedad Chilena de Obesidad.

While PCSK9 inhibitors have existed previously, they were primarily available as monoclonal antibodies requiring subcutaneous injections. Enlicitide is the first in this class to be approved by the FDA as an oral tablet, as reported by Telemundo and The New York Times.

Comparison of LDL Reduction and Administration

The clinical impact of Enlicitide is highlighted by its ability to reduce LDL cholesterol by up to 60%, according to Yahoo Finanzas. This efficacy places it in a similar range to injectable PCSK9 therapies but changes the delivery method for the patient.

The transition to an oral format addresses a primary barrier in cholesterol management: patient adherence to injectable regimens. By providing a pill alternative, Merck aims to expand access to high-potency LDL lowering for patients who cannot tolerate or prefer not to use injections, according to CNN en Español.

Clinical Context for High Cholesterol Treatment

LDL cholesterol, often called “bad” cholesterol, contributes to the buildup of plaque in the arteries. When levels remain high despite the use of statins, physicians typically turn to secondary options. The introduction of an oral PCSK9 inhibitor provides a new tier of treatment for those with familial hypercholesterolemia or other severe lipid disorders, according to the Sociedad Chilena de Obesidad.

The FDA approval process for Enlicitide focused on the drug’s ability to significantly lower LDL without compromising safety profiles compared to existing therapies. The New York Times reports that the drug is positioned to drastically reduce cholesterol levels in patients who require aggressive lipid-lowering therapy.

Availability and Implementation

Merck is the manufacturer behind the newly approved pill. Following the FDA authorization, the drug will be integrated into cardiovascular treatment protocols for patients meeting the specific criteria for PCSK9 inhibition, according to CNN en Español.

Medical providers will likely evaluate Enlicitide for patients who have not reached their LDL targets using maximum-tolerated statin therapy or those who have a high risk of cardiovascular events, based on the therapeutic goals associated with PCSK9 inhibitors described by the Sociedad Chilena de Obesidad.